Discovering Collagen I degradation process in chronic diseases with fibrotic component

MSCA (Marie Skłodowska-Curie)HORIZON-TMA-MSCA-DN-IDID: 101072828
EC Contribution
€16,489
Consortium Size
9 orgs
Start Year
2022
Summary

Fibrosis-related chronic diseases (CDs) are amongst the biggest societal burdens in Europe, with fibrosis being recognised as the main driver of morbidity and mortality. Extracellular matrix (ECM) is a key player in fibrosis, with an excessive accumulation of type I collagen (COL1) being a predominant component of the fibrotic tissue. While the increase in COL1 production is considered a main driver of fibrosis, respective drugs had limited efficacy. New evidence indicates that attenuation of COL1 degradation is highly relevant, contributing to onset and progression of fibrosis. Ambitious early stage researchers (ESRs) will join forces within a multi-disciplinary, comprehensive and inter-sectoral doctorate training programme, embedded in an existing network of excellent research groups across Europe, to investigate the “outside-the-box idea” on impaired COL1 degradation being a key driver of fibrosis. The main scientific goal is to improve the understanding of molecular mechanisms associated with COL1 degradation in major fibrosis-related CDs, and investigate the disruptive hypothesis of attenuated COL1 degradation being the key driver of fibrosis and a major contributor to onset and progression of CDs. This will be achieved through multi-disciplinary research and training combining state-of-the-art –omics approaches and data (peptidomics, proteomics and transcriptomics) in a bioinformatics framework, followed by in- and ex-vivo investigation, complemented with ESRs training on translational skills and competences. Such a programme will train a new generation of translational researchers able to covert ideas into products, and will have a profound impact on their employability, and competitiveness. The project will progress beyond the state of the art and provide the currently missing fundamental knowledge on the molecular pathophysiology of COL1 degradation, setting up the stage for novel biomarkers and anti-fibrotic therapies.

Consortium (9)

Project Results (18)

Source: CORDIS, the EU research results database.

Publications (16)
A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations
International Journal of Molecular Sciences· 2025DOI
Hanne Devos, Ioanna K. Mina, Foteini Paradeisi, Manousos Makridakis, Aggeliki Tserga, Marika Mokou, Jerome Zoidakis, Harald Mischak, Antonia Vlahou, Agnieszka Latosinska, Maria G. Roubelakis
Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients
PROTEOMICS· 2025DOI
Emily M. Martin, Federica Genovese, Harald Mischak, Justyna Siwy, Harald Rupprecht, Lorenzo Catanese, Agnieszka Latosinska
Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities?
Matrix Biology· 2025DOI
Emily M. Martin, Joan Chang, Arantxa González, Federica Genovese
Clinical Proteomics, Quo Vadis?
PROTEOMICS· 2025DOI
Harald Mischak, Joost P. Schanstra, Antonia Vlahou, Joachim Beige
Gut alterations in a chronic kidney disease rat model with diet‐induced vascular calcification
FEBS Open Bio· 2025DOI
Piotr Bartochowski, Irene Cortijo, Shruti Bhargava, Bernard Jover, Fabrice Raynaud, Juliana H Boukhaled, Anne‐Dominique Lajoix, Vera Jankowski, Joachim Jankowski, Magali Cordaillat‐Simmons, Àngel
The Omics‐Driven Machine Learning Path to Cost‐Effective Precision Medicine in Chronic Kidney Disease
PROTEOMICS· 2025DOI
Marta B. Lopes, Roberta Coletti, Flore Duranton, Griet Glorieux, Mayra Alejandra Jaimes Campos, Julie Klein, Matthias Ley, Paul Perco, Alexia Sampri, Aviad Tur‐Sinai
A synthetic data generation pipeline to reproducibly mirror high-resolution multi-variable peptidomics and real-patient clinical data
· 2024DOI
Mayra Alejandra Jaimes Campos, Stipe Kabić, Agnieszka Latosinska, Ena Anicic, Justyna Siwy, Vinko Dragušica, Harald Rupprecht, Lorenzo Catanese, Felix Keller, Paul Perco, Enrique Gomez- Gomez, Joachim Beige, Antonia Vlahou, Harald Mischak, Davorin Vukelić, Tomislav Križan, Maria Frantzi
Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers
International Journal of Molecular Sciences· 2024DOI
Harald Rupprecht, Lorenzo Catanese, Kerstin Amann, Felicitas E. Hengel, Tobias B. Huber, Agnieszka Latosinska, Maja T. Lindenmeyer, Harald Mischak, Justyna Siwy, Ralph Wendt, Joachim Beige
Investigation of the Urinary Peptidome to Unravel Collagen Degradation in Health and Kidney Disease
PROTEOMICS· 2024DOI
Ioanna K. Mina, Luis F. Iglesias‐Martinez, Matthias Ley, Lucas Fillinger, Paul Perco, Justyna Siwy, Harald Mischak, Vera Jankowski
Cafeteria Diet-Induced Obesity Worsens Experimental CKD
Nutrients· 2023DOI
Laget J, Cortijo I, Boukhaled JH, Muyor K, Duranton F, Jover B, Raynaud F, Lajoix AD, Argilés À, Gayrard N
Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study
Pharmaceuticals (Basel)· 2023DOI
Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Mullen W, Schanstra JP, Vlahou A, Rossing K, Peter K, Ortiz A, Campbell A, Persson F, Latosinska A, Mischak H, Siwy J, Jankowski J
Reviewing the Regulators of COL1A1
International Journal of Molecular Sciences· 2023DOI
Devos H, Zoidakis J, Roubelakis MG, Latosinska A, Vlahou A
Urinary peptide analysis to predict the response to blood pressure medication
Nephrology Dialysis Transplantation· 2023DOI
Jaimes Campos MA, Mavrogeorgis E, Latosinska A, Eder S, Buchwinkler L, Mischak H, Siwy J, Rossing P, Mayer G, Jankowski J
Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios
Journal of Translational Medicine· 2023DOI
Keller F, Beige J, Siwy J, Mebazaa A, An D, Mischak H, Schanstra JP, Mokou M, Perco P, Staessen JA, Vlahou A, Latosinska A
Multiple urinary peptides display distinct sex-specific distribution
Proteomics· 2013DOI
Mina IK, Mavrogeorgis E, Siwy J, Stojanov R, Mischak H, Latosinska A, Jankowski V
Benefits and limits of decellularization on mass-spectrometry-based extracellular matrix proteome analysis of mouse kidney
ProteomicsDOI
Frattini, T., Devos, H., Makridakis, M., Roubelakis, M. G., Latosinka, A., Mischak, H., Schanstra, J. P., Vlahou, A., & Saulnier-Blache, J. S
Deliverables (1)
Websites, patent fillings, videos etc.
Other Results (1)
Periodic Reporting for period 1 - DisCo-I (Discovering Collagen I degradation process in chronic diseases with fibrotic component)